Sherly Mosessian, PhD, SOFIE’s Chief Scientific Officer, has been recognized by the organization Women We Admire, as one of the Top 25 Women Chief Scientific [...]

In 2006, the creation of SOFIE launched the aspiration of having a multifaceted approach to expand the reach of PET products for patients with advanced imaging needs. This was further …

Transparency in Coverage (TiC) regulations requires health insurers and group Health Plans to post their provider link on company websites. View SOFIE’s Link here View our Privacy Policy

In Nov 2019, SOFIE Biosciences (SOFIE) licensed quinoline-based PET tracers, developed by the team at Heidelberg University, that act as FAP inhibitors (FAPI) and showed promising …

SOFIE is dedicated to providing reliable, high quality radiopharmaceuticals and cutting-edge technologies

SOFIE has built a high-capacity PET radiopharmaceutical network capable of delivering large volumes of products to as many patients as possible. Our product lines include FDG, Pylarify, …

Our team works alongside our Pharma and Academic partners to revolutionize clinical diagnostics and therapeutics to better understand and treat the biology of disease.

GE HealthCare and SOFIE Biosciences (SOFIE) announced a partnership to develop, manufacture and commercialize SOFIE’s Gallium-68 and Fluorine-18 labelled diagnostics …

Oct 1, 2025 · With its robust radiopharmaceutical production and distribution network, mature contract manufacturing services, and now, high-value theranostic intellectual property, SOFIE …

NEW YORK (June 4, 2024) – Trilantic North America, a growth-focused middle market private equity firm, announced today that it has made a substantial growth investment in SOFIE …